Literature DB >> 32793890

Mutational landscape and patterns of clonal evolution in relapsed pediatric acute lymphoblastic leukemia.

Esmé Waanders1,2,3, Zhaohui Gu1, Stephanie M Dobson4,5, Željko Antić2, Roland P Kuiper2, Charles G Mullighan6, Jeremy Chase Crawford7, Xiaotu Ma8, Michael N Edmonson8, Debbie Payne-Turner1, Maartje van de Vorst9, Marjolijn C J Jongmans2,3, Irina McGuire10, Xin Zhou8, Jian Wang8, Lei Shi11, Stanley Pounds11, Deqing Pei11, Cheng Cheng11, Guangchun Song1, Yiping Fan8, Ying Shao8, Michael Rusch8, Kelly McCastlain1, Jiangyan Yu2, Ruben van Boxtel2, Francis Blokzijl12,13, Ilaria Iacobucci1, Kathryn G Roberts1, Ji Wen1, Gang Wu8, Jing Ma1, John Easton8, Geoffrey Neale14, Scott R Olsen14, Kim E Nichols15, Ching-Hon Pui15, Jinghui Zhang8, William E Evans16, Mary V Relling16, Jun J Yang16, Paul G Thomas7, John E Dick4,5.   

Abstract

Relapse of acute lymphoblastic leukemia (ALL) remains a leading cause of childhood death. Prior studies have shown clonal mutations at relapse often arise from relapse-fated subclones that exist at diagnosis. However, the genomic landscape, evolutionary trajectories and mutational mechanisms driving relapse are incompletely understood. In an analysis of 92 cases of relapsed childhood ALL, incorporating multimodal DNA and RNA sequencing, deep digital mutational tracking and xenografting to formally define clonal structure, we identify 50 significant targets of mutation with distinct patterns of mutational acquisition or enrichment. CREBBP, NOTCH1, and Ras signaling mutations rose from diagnosis subclones, whereas variants in NCOR2, USH2A and NT5C2 were exclusively observed at relapse. Evolutionary modeling and xenografting demonstrated that relapse-fated clones were minor (50%), major (27%) or multiclonal (18%) at diagnosis. Putative second leukemias, including those with lineage shift, were shown to most commonly represent relapse from an ancestral clone rather than a truly independent second primary leukemia. A subset of leukemias prone to repeated relapse exhibited hypermutation driven by at least three distinct mutational processes, resulting in heightened neoepitope burden and potential vulnerability to immunotherapy. Finally, relapse-driving sequence mutations were detected prior to relapse using deep digital PCR at levels comparable to orthogonal approaches to monitor levels of measurable residual disease. These results provide a genomic framework to anticipate and circumvent relapse by earlier detection and targeting of relapse-fated clones.

Entities:  

Keywords:  acute lymphoblastic leukemia; clonal evolution; genomics; hypermutation; neoepitopes; relapse

Mesh:

Year:  2020        PMID: 32793890      PMCID: PMC7418874          DOI: 10.1158/0008-5472.BCD-19-0041

Source DB:  PubMed          Journal:  Blood Cancer Discov        ISSN: 2643-3230


  66 in total

1.  CREBBP mutations in relapsed acute lymphoblastic leukaemia.

Authors:  Charles G Mullighan; Jinghui Zhang; Lawryn H Kasper; Stephanie Lerach; Debbie Payne-Turner; Letha A Phillips; Sue L Heatley; Linda Holmfeldt; J Racquel Collins-Underwood; Jing Ma; Kenneth H Buetow; Ching-Hon Pui; Sharyn D Baker; Paul K Brindle; James R Downing
Journal:  Nature       Date:  2011-03-10       Impact factor: 49.962

2.  Mutational Strand Asymmetries in Cancer Genomes Reveal Mechanisms of DNA Damage and Repair.

Authors:  Nicholas J Haradhvala; Paz Polak; Petar Stojanov; Kyle R Covington; Eve Shinbrot; Julian M Hess; Esther Rheinbay; Jaegil Kim; Yosef E Maruvka; Lior Z Braunstein; Atanas Kamburov; Philip C Hanawalt; David A Wheeler; Amnon Koren; Michael S Lawrence; Gad Getz
Journal:  Cell       Date:  2016-01-21       Impact factor: 41.582

3.  Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia.

Authors:  Charles G Mullighan; Letha A Phillips; Xiaoping Su; Jing Ma; Christopher B Miller; Sheila A Shurtleff; James R Downing
Journal:  Science       Date:  2008-11-28       Impact factor: 47.728

4.  Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia.

Authors:  Charles G Mullighan; Xiaoping Su; Jinghui Zhang; Ina Radtke; Letha A A Phillips; Christopher B Miller; Jing Ma; Wei Liu; Cheng Cheng; Brenda A Schulman; Richard C Harvey; I-Ming Chen; Robert J Clifford; William L Carroll; Gregory Reaman; W Paul Bowman; Meenakshi Devidas; Daniela S Gerhard; Wenjian Yang; Mary V Relling; Sheila A Shurtleff; Dario Campana; Michael J Borowitz; Ching-Hon Pui; Malcolm Smith; Stephen P Hunger; Cheryl L Willman; James R Downing
Journal:  N Engl J Med       Date:  2009-01-07       Impact factor: 91.245

5.  A flexible R package for nonnegative matrix factorization.

Authors:  Renaud Gaujoux; Cathal Seoighe
Journal:  BMC Bioinformatics       Date:  2010-07-02       Impact factor: 3.169

6.  Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia.

Authors:  Xiaotu Ma; Michael Edmonson; Donald Yergeau; Donna M Muzny; Oliver A Hampton; Michael Rusch; Guangchun Song; John Easton; Richard C Harvey; David A Wheeler; Jing Ma; HarshaVardhan Doddapaneni; Bhavin Vadodaria; Gang Wu; Panduka Nagahawatte; William L Carroll; I-Ming Chen; Julie M Gastier-Foster; Mary V Relling; Malcolm A Smith; Meenakshi Devidas; Jaime M Guidry Auvil; James R Downing; Mignon L Loh; Cheryl L Willman; Daniela S Gerhard; Charles G Mullighan; Stephen P Hunger; Jinghui Zhang
Journal:  Nat Commun       Date:  2015-03-19       Impact factor: 14.919

7.  HTSeq--a Python framework to work with high-throughput sequencing data.

Authors:  Simon Anders; Paul Theodor Pyl; Wolfgang Huber
Journal:  Bioinformatics       Date:  2014-09-25       Impact factor: 6.937

8.  Clock-like mutational processes in human somatic cells.

Authors:  Ludmil B Alexandrov; Philip H Jones; David C Wedge; Julian E Sale; Peter J Campbell; Serena Nik-Zainal; Michael R Stratton
Journal:  Nat Genet       Date:  2015-11-09       Impact factor: 38.330

9.  NBPF1, a tumor suppressor candidate in neuroblastoma, exerts growth inhibitory effects by inducing a G1 cell cycle arrest.

Authors:  Vanessa Andries; Karl Vandepoele; Katrien Staes; Geert Berx; Pieter Bogaert; Gert Van Isterdael; Daisy Ginneberge; Eef Parthoens; Jonathan Vandenbussche; Kris Gevaert; Frans van Roy
Journal:  BMC Cancer       Date:  2015-05-10       Impact factor: 4.430

10.  SciClone: inferring clonal architecture and tracking the spatial and temporal patterns of tumor evolution.

Authors:  Christopher A Miller; Brian S White; Nathan D Dees; Malachi Griffith; John S Welch; Obi L Griffith; Ravi Vij; Michael H Tomasson; Timothy A Graubert; Matthew J Walter; Matthew J Ellis; William Schierding; John F DiPersio; Timothy J Ley; Elaine R Mardis; Richard K Wilson; Li Ding
Journal:  PLoS Comput Biol       Date:  2014-08-07       Impact factor: 4.475

View more
  36 in total

Review 1.  Molecular markers in ALL: Clinical implications.

Authors:  Shunsuke Kimura; Charles G Mullighan
Journal:  Best Pract Res Clin Haematol       Date:  2020-06-07       Impact factor: 3.020

2.  Chemotherapy and mismatch repair deficiency cooperate to fuel TP53 mutagenesis and ALL relapse.

Authors:  Fan Yang; Samuel W Brady; Chao Tang; Huiying Sun; Lijuan Du; Malwine J Barz; Xiaotu Ma; Yao Chen; Houshun Fang; Xiaomeng Li; Pandurang Kolekar; Omkar Pathak; Jiaoyang Cai; Lixia Ding; Tianyi Wang; Arend von Stackelberg; Shuhong Shen; Cornelia Eckert; Jeffery M Klco; Hongzhuan Chen; Caiwen Duan; Yu Liu; Hui Li; Benshang Li; Renate Kirschner-Schwabe; Jinghui Zhang; Bin-Bing S Zhou
Journal:  Nat Cancer       Date:  2021-07-22

Review 3.  T-cell Acute Lymphoblastic Leukemia: A Roadmap to Targeted Therapies.

Authors:  Valentina Cordo'; Jordy C G van der Zwet; Kirsten Canté-Barrett; Rob Pieters; Jules P P Meijerink
Journal:  Blood Cancer Discov       Date:  2020-11-24

4.  Deciphering the Clonal Origin of Relapsed Acute Lymphoblastic Leukemia in Children.

Authors:  Seishi Ogawa
Journal:  Blood Cancer Discov       Date:  2020-06-22

5.  Molecular characterization of an embryonal rhabdomyosarcoma occurring in a patient with Kabuki syndrome: report and literature review in the light of tumor predisposition syndromes.

Authors:  Sietse M Aukema; Selina Glaser; Mari F C M van den Hout; Sonja Dahlum; Marinus J Blok; Morten Hillmer; Julia Kolarova; Raf Sciot; Dina A Schott; Reiner Siebert; Constance T R M Stumpel
Journal:  Fam Cancer       Date:  2022-07-19       Impact factor: 2.446

Review 6.  Childhood Acute Leukemias in Developing Nations: Successes and Challenges.

Authors:  Marta Zapata-Tarrés; Juan Carlos Balandrán; Roberto Rivera-Luna; Rosana Pelayo
Journal:  Curr Oncol Rep       Date:  2021-03-23       Impact factor: 5.075

Review 7.  Advances in germline predisposition to acute leukaemias and myeloid neoplasms.

Authors:  Jeffery M Klco; Charles G Mullighan
Journal:  Nat Rev Cancer       Date:  2020-12-16       Impact factor: 60.716

Review 8.  MRD-Based Therapeutic Decisions in Genetically Defined Subsets of Adolescents and Young Adult Philadelphia-Negative ALL.

Authors:  Manuela Tosi; Orietta Spinelli; Matteo Leoncin; Roberta Cavagna; Chiara Pavoni; Federico Lussana; Tamara Intermesoli; Luca Frison; Giulia Perali; Francesca Carobolante; Piera Viero; Cristina Skert; Alessandro Rambaldi; Renato Bassan
Journal:  Cancers (Basel)       Date:  2021-04-27       Impact factor: 6.639

Review 9.  ER Stress and Unfolded Protein Response in Leukemia: Friend, Foe, or Both?

Authors:  Kelly Féral; Manon Jaud; Céline Philippe; Doriana Di Bella; Stéphane Pyronnet; Kevin Rouault-Pierre; Laurent Mazzolini; Christian Touriol
Journal:  Biomolecules       Date:  2021-01-30

10.  Mutational patterns and clonal evolution from diagnosis to relapse in pediatric acute lymphoblastic leukemia.

Authors:  Shumaila Sayyab; Anders Lundmark; Malin Larsson; Markus Ringnér; Sara Nystedt; Yanara Marincevic-Zuniga; Katja Pokrovskaja Tamm; Jonas Abrahamsson; Linda Fogelstrand; Mats Heyman; Ulrika Norén-Nyström; Gudmar Lönnerholm; Arja Harila-Saari; Eva C Berglund; Jessica Nordlund; Ann-Christine Syvänen
Journal:  Sci Rep       Date:  2021-08-06       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.